Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.72 |
| ▸ | PDE4A | P27815 | 10/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | PDE1A | P54750 | 1/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.57 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533141 | 0.92 | PDE4B (0.66) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2229915 | 0.89 | PDE4B (0.77) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2531972 | 0.89 | PDE4B (0.77) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL8004429 | 0.88 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL15012063 | 0.87 | PDE4B (0.66) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2533367 | 0.87 | PDE4B (0.80) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2528906 | 0.86 | PDE4B (0.79) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2527180 | 0.86 | PDE4B (0.78) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL12432118 | 0.86 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2528238 | 0.86 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2564857-B1 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | claimed |
| EP-2564857-A1 | Boron-containing small molecules as anti-inflammatory agents | Anacor Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| EP-3246034-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246034-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2564857-B1 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2564857-B1 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9499570-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416146-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416146-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20120214765-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2011094450-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-2187893-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009111676-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111676-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
| US-20120214765-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.